Analytical Data
-
基因名
INHA
- Application
-
别名
INHA；Inhibin alpha chain
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P05111
-
表达区间
19-366aa
-
氨基酸序列
CQGLELARELVLAKVRALFLDALGPPAVTREGGDPGVRRLPRRHALGGFT HRGSEPEEEEDVSQAILFPATDASCEDKSAARGLAQEAEEGLFRYMFRPS QHTRSRQVTSAQLWFHTGLDRQGTAASNSSEPLLGLLALSPGGPVAVPMS LGHAPPHWAVLHLATSALSLLTHPVLVLLLRCPLCTCSARPEATPFLVAH TRTRPPSGGERARRSTPLMSWPWSPSALRLLQRPPEEPAAHANCHRVALN ISFQELGWERWIVYPPSFIFHYCHGGCGLHIPPNLSLPVPGAPPTPAQPY SLLPGAQPCCAALPGTMRPLHVRTTSDGGYSFKYETVPNLLTQHCACI
-
分子量
38 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
INHA, also known as Inhibin Alpha, is a member of the inhibin family of proteins, which play crucial roles in regulating reproductive processes, particularly in the inhibition of follicle-stimulating hormone (FSH) secretion from the pituitary gland. The research into recombinant INHA proteins has gained importance due to their potential applications in reproductive medicine and fertility treatments. By producing these proteins through recombinant DNA technology, researchers aim to study their biological functions and mechanisms in more detail. Understanding the structure and activity of INHA can lead to novel therapeutic strategies for conditions such as polycystic ovary syndrome (PCOS) and infertility, where the normal regulatory functions of inhibins may be disrupted. Additionally, recombinant INHA proteins offer opportunities for the development of diagnostic tools and treatments that can enhance reproductive health. The advancement of INHA research is, therefore, significant not only for basic reproductive biology but also for improving clinical outcomes in assisted reproductive technologies and managing hormone-related disorders.
